TP53 and breast carcinoma: We discovered that high expression of MELK in p53-mutant breast cancers is due to the loss of WT p53 activity, which normally functions in p53 WT cells by repressing E2F1A binding to the FOXM1 promoter, which reduces FOXM1 expression and, in turn, MELK expression.